Source-grounded facts extracted from Telomir Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Andriy Mushak was appointed as fractional Chief Financial Officer at Telomir Pharmaceuticals, Inc..
“On June 3, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company’s fractional Chief Financial Officer, effective as of June 6, 2026”
Alan Weichselbaum departed as Chief Financial Officer at Telomir Pharmaceuticals, Inc..
“Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Telomir Pharmaceuticals, Inc. (the "Company"). Mr. Weichselbaum’s departure was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.”
Telomir Pharmaceuticals, Inc. completed an acquisition involving TELI Pharmaceuticals, Inc. for 34,389,710 restricted shares of the Company’s common stock (closed 2026-04-22).
“by the Company’s shareholders during the Company’s annual shareholders meeting on March 23, 2026. At closing, the Company acquired 100% of TELI in exchange for a total of 34,389,710 restricted shares of the Company’s common stock, no par value issued to TELI’s former shareholders (the “Shares”). The number of shares issued was determined based on an exchange”
Telomir Pharmaceuticals, Inc. entered into Commitment Agreement with Bayshore Trust (effective 2026-04-22).
“On April 22, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) completed its acquisition of TELI Pharmaceuticals, Inc. (“TELI”) pursuant to the previously announced merger agreement (the “Transaction”).”
Telomir Pharmaceuticals, Inc.: Reduced quorum requirement for shareholder meetings to one-third (effective 2026-03-23).
“the Company’s shareholders approved an amendment to the Bylaws of the Company to reduce the amount required for a quorum for an action by the Company’s shareholders adopted in a meeting to one-third.”
Telomir Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).
“January 8, 2026, the Company received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a), which requires listed companies to hold an annual meeting of shareholders within twelve months of the end of their fiscal year. The Notice does not result in the immediate delisting of the Company’s securities and has no current effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market. Pursuant to the Notice, the Company has”
Alan Weichselbaum was appointed as Chief Financial Officer at Telomir Pharmaceuticals, Inc..
“On May 15, 2025, the Company entered into an Employment Agreement (the “Employment Agreement”) with Mr. Weichselbaum to serve as chief financial officer of the Company beginning on May 19, 2025 (the “Start Date”).”
Michelle Yanez resigned as Chief Financial Officer at Telomir Pharmaceuticals, Inc..
“Effective May 16, 2025, Michelle Yanez and the Company mutually agreed to release Ms. Yanez from her position as Chief Financial Officer, Treasurer and Secretary of Telomir Pharmaceuticals, Inc. (the “Company”), effective on that date.”
Telomir Pharmaceuticals, Inc. engaged Salberg & Company P.A. as its auditor.
“On December 18 th , 2024, the Company engaged Salberg & Company P.A. (“Salberg”) as its new independent registered public accountant for the fiscal year ending December 31, 2024.”
Cherry Bekaert LLP resigned as auditor of Telomir Pharmaceuticals, Inc..
“By letter dated December 16, 2024, Cherry Bekaert LLP (“Cherry Bekaert”) notified the Audit Committee of the Board of Directors (the “Audit Committee”) of Telomir Pharmaceuticals, Inc’s (the “Company”) of its resignation as the Company’s independent registered public accounting firm.”
Michael Jerman resigned as Member of the Board of Directors and Chair of the Audit Committee at Telomir Pharmaceuticals, Inc..
“On November 18, 2024, Telomir Pharmaceuticals, Inc. (the “ Company ”) received written notice of resignation from Michael Jerman resigning, with immediate effect, from his positions a member of the Board of Directors of the Company (the “ Board ”) and as Chair of the Audit Committee”
Michelle Yanez was appointed as Chief Financial Officer at Telomir Pharmaceuticals, Inc..
“On June 18, 2024, the Board of the Company appointed Michelle Yanez, MBA as the Chief Financial Officer, of the Company.”
Nathan Fuentes resigned as Chief Financial Officer at Telomir Pharmaceuticals, Inc..
“On June 18, 2024, Telomir Pharmaceuticals, Inc. (the “ Company ”) and Nathen Fuentes entered into a Confidential Separation and Mutual General Release Agreement (the “ Separation Agreement ”) whereby both the Company and Mr. Fuentes mutually agreed that Mr. Fuentes’ employment as a Chief Financial Officer of the Company would end as of June 18, 2024.”
Christos Nicholoudis resigned as Board Member at Telomir Pharmaceuticals, Inc..
“On April 10, 2024, Telomir Pharmaceuticals, Inc. (the “Company”) received written notice of resignation from Christos Nicholoudis, Esq. resigning, with immediate effect, from his positions as the General Counsel and a member of the Board of Directors of the Company.”
Christos Nicholoudis resigned as General Counsel at Telomir Pharmaceuticals, Inc..
“On April 10, 2024, Telomir Pharmaceuticals, Inc. (the “Company”) received written notice of resignation from Christos Nicholoudis, Esq. resigning, with immediate effect, from his positions as the General Counsel and a member of the Board of Directors of the Company.”
Telomir Pharmaceuticals, Inc. entered into Underwriting Agreement with Kingswood Investments, division of Kingswood Capital Partners, LLC valued at $7,000,000 (effective 2024-02-08).
“On February 8, 2024, Telomir Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement with Kingswood Investments, division of Kingswood Capital Partners, LLC (“Kingswood”) on behalf of itself and as representative of the underwriters named therein (the “Underwriting Agreement”), pursuant to which the Company issued and sold, in an underwritten public offering (the “Public Offering”), 1,000,000 shares of common stock, no par value (“Common Stock”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.